Men Have Higher Risk of Parkinson's, And We May Finally Know Why
The risk of developing Parkinson's disease is twice as high in men as in women, and new research points to a potential reason why: a normally benign protein in the brain.
PTEN-induced kinase 1 (PINK1) protein is not normally a threat, and is important in regulating cellular energy use in the brain. However, the new research shows that in some Parkinson's cases, the immune system mistakes PINK1 for an enemy, attacking brain cells that express the protein.
According to the study, led by a team from the La Jolla Institute for Immunology in California, the PINK1-related damage done by the immune system's T cells is much more widespread and aggressive in the brains of men than women.
"The sex-based differences in T cell responses were very, very striking," says immunologist Alessandro Sette, from the La Jolla Institute for Immunology. "This immune response may be a component of why we see a sex difference in Parkinson's disease."
Using blood samples from Parkinson's patients, the researchers tested the response of the T cells in the blood against a variety of proteins previously linked to Parkinson's – finding that PINK1 stood out.
In the male Parkinson's patients, the research team noticed a six-fold increase in T cells targeting PINK1-tagged brain cells, compared with healthy brains. In the female Parkinson's patients, there was only a 0.7-fold increase.
Some of the same researchers had previously found something similar happening with T cells and the alpha-synuclein protein. However, these reactions weren't common to all Parkinson's brains, which prompted the hunt for more antigens – substances that trigger immune responses.
As is always the case with research of this type, once experts know more about how a disease gets started and how it progresses, that opens up new opportunities for finding ways to put a halt to the damage.
"We could potentially develop therapies to block these T cells, now that we know why the cells are targeting in the brain," says immunologist Cecilia Lindestam Arlehamn, from the La Jolla Institute for Immunology.
Further down the line, being able to spot these PINK1-sensitive T cells in blood samples could lead to Parkinson's disease being diagnosed at an earlier stage – which again helps with treatment and patient support.
While we're still waiting to discover a cure for Parkinson's disease, constant progress is being made in understanding the risk factors involved in its development, and new approaches to tackling it.
"We need to expand to perform more global analysis of the disease progression and sex differences – considering all the different antigens, disease severities, and time since disease onset," says Sette.
The research has been published in the Journal of Clinical Investigation.
An Ancient Disease Has Reappeared in The US. This Could Be Why.
Daylight Saving Disrupts Millions of Americans. There's a Better Way.
This Common Blood Pressure Drug Extends Lifespan And Slows Aging in Animals
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Joe Biden 'optimistic' about treatment plan for Stage 4 prostate cancer
Former President Joe Biden said on May 30 that he is 'optimistic' about the treatment plan for his Stage 4 prostate cancer, which involves taking a daily pill for six weeks. "We're underway and all the folks are very optimistic," Biden said. 'The expectation is we're going to be able to beat this. It's not in any (other) organ. My bones are strong, it hasn't penetrated. So I'm feeling good.' More: Biden urges Americans to support veterans on anniversary of son Beau's death Doctors found a 'small nodule' on Biden's prostate during a routine exam; the 82-year-old was diagnosed Friday, May 16, according to a statement released by his office. Speaking to reporters at a Delaware Memorial Day event for the first time since announcing his diagnosis, Biden said that he is being treated by a top doctor in the field. Biden's physician has lived through the same aggressive form of cancer as the former president. 'We're all optimistic about the diagnosis. Matter of fact, one of the leading surgeons in the world is working with me and he was diagnosed with the same exact thing 32 years ago,' Biden said. 'He's alive and well, doing very well.' Biden spoke with reporters as he left the annual Memorial Day event at Veterans Memorial Park in New Castle, Delaware, which coincided with the 10th anniversary of his son Beau Biden's death. It was also the first time Biden spoke to reporters since a book was published raising questions about his physical and mental fitness while he was president. A White House spokeswoman alleged Thursday that former first lady Jill Biden conspired to keep her husband's health from the American people. When asked to respond, Biden, who had just given a 10-minute speech and walked over to the throng of reporters, joked, "You can see that I'm mentally incompetent and I can't walk." This article originally appeared on USA TODAY: Joe Biden 'optimistic' about cancer treatment, doctor, meds
Yahoo
29 minutes ago
- Yahoo
California petitions FDA to undo RFK Jr.'s new limits on abortion pill mifepristone
California and three other states petitioned the U.S. Food and Drug Administration Thursday to ease its new restrictions on the abortion pill mifepristone, citing the drug's proven safety record and arguing the new limits are unnecessary. "The medication is a lifeline for millions of women who need access to time-sensitive, critical healthcare — especially low-income women and those who live in rural and underserved areas," said California Atty. Gen. Rob Bonta, who filed the petition alongside the attorneys general of Massachusetts, New York and New Jersey. The petition cites Senate testimony by Health and Human Services Secretary Robert F. Kennedy Jr. last month, in which Kennedy said he had ordered FDA administrator Martin Makary to conduct a "complete review" of mifepristone and its labeling requirements. The drug, which can be received by mail, has been on the U.S. market for 25 years and taken safely by millions of Americans, according to experts. It is the most common method of terminating a pregnancy in the U.S., with its use surging after the Supreme Court overturned Roe vs. Wade in 2022. The Supreme Court upheld access to the drug for early pregnancies under previous FDA regulations last year, but it has remained a target of anti-abortion conservatives. The Trump administration has given Kennedy broad rein to shake up American medicine under his "Make America Healthy Again" banner, and Kennedy has swiftly rankled medical experts by using dubious science — and even fake citations — to question vaccine regimens and research and other longstanding public health measures. Read more: Hiltzik: MAHA report's misrepresentations will harm public health and hit consumers' pocketbooks At the Senate hearing, Kennedy cited "new data" from a flawed report pushed by anti-abortion groups — and not published in any peer-reviewed journal — to question the safety of mifepristone, calling the report "alarming." "Clearly, it indicates that, at very least, the label should be changed," Kennedy said. Sen. Josh Hawley (R-Mo.) on Monday posted a letter from Makary to X, in which Makary wrote that he was "committed to conducting a review of mifepristone" alongside "the professional career scientists" at the FDA. Makary said he could not provide additional information given ongoing litigation around the drug. The states, in their 54-page petition, wrote that "no new scientific data has emerged since the FDA's last regulatory actions that would alter the conclusion that mifepristone remains exceptionally safe and effective," and that studies "that have frequently been cited to undermine mifepristone's extensive safety record have been widely criticized, retracted, or both." Democrats have derided Kennedy's efforts to reclassify mifepristone as politically motivated and baseless. "This is yet another attack on women's reproductive freedom and scientifically-reviewed health care," Gov. Gavin Newsom said the day after Kennedy's Senate testimony. "California will continue to protect every person's right to make their own medical decisions and help ensure that Mifepristone is available to those who need it." Bonta said Thursday that mifepristone's placement under the FDA's Risk Evaluation and Mitigation Strategy program for drugs with known, serious side effects — or REMS — was "medically unjustified," unduly burdened patient access and placed "undue strain on the nation's entire health system." He said mifepristone "allows people to get reproductive care as early as possible when it is safest, least expensive, and least invasive," is "so safe that it presents lower risks of serious complications than taking Tylenol," and that its long safety record "is backed by science and cannot be erased at the whim of the Trump Administration." Read more: Q&A: The FDA says the abortion pill mifepristone is safe. Here's the evidence The FDA has previously said that fewer than 0.5% of women who take the drug experience 'serious adverse reactions,' and deaths are exceedingly rare. The REMS program requires prescribers to add their names to national and local abortion provider lists, which can be a deterrent for doctors given safety threats, and pharmacies to comply with complex tracking, shipping and reporting requirements, which can be a deterrent to carrying the drug, Bonta said. It also requires patients to sign forms in which they attest to wanting to "end [their] pregnancy," which Bonta said can be a deterrent for women using the drug after a miscarriage — one of its common uses — or for those in states pursuing criminal penalties for women seeking certain abortion care. Under federal law, REMS requirements must address a specific risk posed by a drug and cannot be "unduly burdensome" on patients, and the new application to mifepristone "fails to meet that standard," Bonta said. The states' petition is not a lawsuit, but a regulatory request for the FDA to reverse course, the states said. If the FDA will not do so nationwide, the four petitioning states asked that it "exercise its discretion to not enforce the requirements" in their states, which Bonta's office said already have "robust state laws that ensure safe prescribing, rigorous informed consent, and professional accountability." Get the L.A. Times Politics newsletter. Deeply reported insights into legislation, politics and policy from Sacramento, Washington and beyond, in your inbox twice per week. This story originally appeared in Los Angeles Times.
New York Post
an hour ago
- New York Post
Botox may increase your face value — but you're better off trying this move that doesn't cost a cent, scientists say
Dolly Parton was right. Botox may increase face value for a growing number of Americans, including celebs like Nicole Kidman and Meghan Trainor — but when it comes to making yourself desirable to a prospective partner, researchers say smiling can be even more effective. New research suggests that the popular cosmetic injections do increase users' curb appeal — but when respondents in a survey were asked to rate an array of strange faces, those with upturned lips beat those who merely plumped them up. 4 The research found that smiling could be more effective at enhancing visual appeal than filler injections (pictured). Stasique – Scientists at Tilburg University in The Netherlands also reported that Botox users were likely to be seen as one-night stand prospects — and that getting the costly jabs weren't necessarily useful to those hoping to be taken more seriously as viable life partners. The illusion-shattering findings, published in the journal 'Perception,' come amid a worldwide uptick in Botox usage. Usage of the injectable 'tweakment' has become so frequent that people are actually developing an immunity. Researchers set out to test if people who undergo Botox and other filler treatments are perceived 'more positively by others,' per study co-author Dr. Bastian Jaeger, who claimed that 'existing research on the effectiveness of these treatments is not very strong.' To see if it's worth literally putting one's money where their mouth is, the scientists followed 114 participants who underwent Botox and dermal filler treatments, the Times Of London reported. 4 Study authors found that while Botox can make you more attractive as a mate, it won't necessarily get you to happily ever after any faster. Vasyl – They then asked around 3,000 people to rate their before and after pics on a 7-point attractiveness scale. After reviewing said snaps, which were shot carefully to keep the lighting, expression and other factors consistent across the pics, participants overwhelmingly found that Botox does indeed boost people's visual appeal. 'This difference was rather small: a 0.07-point change in our 7-point attractiveness scale on average,' explained Dr. Jaeger per the Daily Mail. 'This means that on average, a person who was rated a 4 out of 7 on attractiveness before the treatment might be rated a 4.07 out of 7 after treatment.' 4 Participants were asked to evaluate the before-and-after pics of Botox recipients. Sage Journals There was also an increase of 0.13 with regards to how youthful the participants were thought of. However, this paled in comparison to another, less expensive way of enhancing one's attractiveness: smiling. Researchers found that turning one's frown upside down — and not cosmetically — caused one's so-called hotness to soar by 0.4 points, six times more than Botox. 4 'We did not see any benefits of treatment on how competent, intelligent, charismatic, friendly or trustworthy people were perceived to be,' said Jaeger. Drobot Dean – Meanwhile, applying makeup gave people's perceived looks a boost of 0.6 points compared to the filler treatment, which starts at around $300 for a simple forehead injection and involves obstructing nerve signals to muscles, relaxing them and curbing wrinkles. There was another major caveat to alleged Botox-enhanced hotness. While the aesthetic accelerant increased people's desirability as a short-term fling prospect and as a platonic pal — a rise of 0.09 in both categories — there was no statistical improvement in how they were seen as long-term partners. It's unclear why Botox didn't up people's image as soulmate material, but scientists noted that the jabs had no effect on the perception of character traits either. 'We did not see any benefits of treatment on how competent, intelligent, charismatic, friendly or trustworthy people were perceived to be,' said Jaeger. Interestingly, while small amounts of botox did not significantly enhance physical appeal, many people report that, 'after treatment, they find it easier to make friends and that they make a better impression on others,' per Jaeger. Dr. Jaeger attributed this phenomenon to a placebo effect of sorts. 'It is plausible that people have more success socially, not because they look different and people treat them differently, but because they think they do and act more confidently around others (sort of a self-fulfilling prophecy),' he said.
